NPHLA Daily — October 9, 2026

Good morning. Here is what changed across metabolic medicine, pharmacy regulation, aesthetics and healthcare technology since yesterday — every item linked to its source.

Top development today

What changed today in Metabolic: 4 new studies, 3 trial updates

NPHLA tracked 7 new official records on this desk today: 3 trial updates, 4 new studies. First: New trial registered: TIFFANY (Trial of Innovative Fat-loss Focused Approaches in Patients With Class I Obesity: a Comparative Study)

Metabolic signal

Preventing Weight Regain After Glucagon-Like Peptide‑1 Therapy Discontinuation: A Pilot Randomized Controlled Trial

From Obesity science & practice.

Regulatory signal

What changed today in Regulatory: 1 proposed rule

NPHLA tracked 1 new official record on this desk today: 1 proposed rule. First: Proposed rule published: Requirements for Additional Traceability Records for Certain Foods: Enforcement Policy for Certain Retail Food Establishments and Restaurants; Draft Guidance for Industry;….

Aesthetics & Longevity signal

What changed today in Aesthetics & Longevity: 1 new study, 1 trial update

NPHLA tracked 2 new official records on this desk today: 1 new study, 1 trial update. First: New research in Tissue & cell: “Exosome-loaded hydrogel promotes tissue repair in Staphylococcus aureus-infected cutaneous wounds: Histological and immunohistochemical evidence of…

One thing worth watching

Comments close: Agency Information Collection Activities; Proposed Collection; Comment Request; Registration of Human Drug Compounding Outsourcing Facilities Under the Federal Food, Drug, and…

October 29, 2026 — verified from the Federal Register comments_close_on.

5 things to know

Compiled by NPHLA Intelligence from published briefings and official records. Professional information only — not medical or legal advice. Our standards.